CommercialAdministrativeLow impact
08.01.83d, Tisotumab vedotin-tftv (Tivdak®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
The policy for Tisotumab vedotin-tftv (Tivdak®), a specialty oncology medication, has been reissued for commercial plans. This appears to be an administrative reissue rather than a substantive policy change, but billing teams should verify current coverage and billing requirements for this cancer treatment drug.
Action Required
By April 1, 2026: Billing team should review the full updated policy at the provided URL to confirm current coverage criteria, prior authorization requirements, and billing procedures for Tisotumab vedotin-tftv (Tivdak®). Verify any changes to HCPCS J-codes or administration requirements for this specialty oncology medication.